Baxter International Inc. (BAX) Revenue by Segment

Baxter International revenue by segment at a glance

In Q2 fiscal 2026 (the quarter ended June 30, 2026), Baxter International's largest business segment was Medical Products and Therapies, with $2.08 billion or 72% of revenue, up 6.7% from a year earlier. Next: Healthcare Systems and Technologies (28%).

By product or service, Infusion Therapies and Platforms brought in 61%, Care and Connectivity Solutions brought in 17% and Advanced Surgery brought in 12% of revenue in Q2 fiscal 2026.

By region, United States brought in 54% and Non-US brought in 46% of revenue in Q2 fiscal 2026.

The fastest-growing business segment from a year earlier was Medical Products and Therapies (+6.7%).

From company filings, in USD; latest quarter ended June 30, 2026; quarterly data from Q3 fiscal 2017.

Baxter International Inc.

BAXHealthcare

United States

Healthcare

Revenue breakdown

Fiscal quarters, from company filings

Segments by quarter (USD)

Click a bar to see that period below. Striped bars are calculated fourth quarters; an empty slot means it could not be calculated on the same basis i

AmericasMedical Products and TherapiesEMEAHealthcare Systems and TechnologiesAsia PacificPharmaceuticalsHillromKidney CareOther

Q2 FY26 breakdown

Fiscal quarter ended Jun 30, 2026

Item	Revenue	Share	vs year before
Medical Products and Therapies	USD 2.08B	72.2%	+6.7%
Healthcare Systems and Technologies	USD 801.00M	27.8%	+4.4%
Corporate and otheri	USD 83.00M		-15.3%

Sum of items USD 2.88B; corporate items and eliminations USD 83.00M. Shares are of the items shown. Click an item with › to see its parts.

Also reported by:

All periods

Every item and period in one grid. Purple = calculated; "–" = not available.

Item	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24	Q1 FY24	Q4 FY23	Q3 FY23	Q2 FY23	Q1 FY23	Q4 FY22	Q3 FY22	Q2 FY22	Q1 FY22	Q4 FY21	Q3 FY21	Q2 FY21	Q1 FY21	Q4 FY20	Q3 FY20	Q2 FY20	Q1 FY20	Q4 FY19	Q3 FY19	Q2 FY19	Q1 FY19	Q4 FY18	Q3 FY18	Q2 FY18	Q1 FY18	Q4 FY17	Q3 FY17
Americas	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1.5B	1.6B	–	1.7B	1.6B	1.6B	–	1.5B	1.5B	1.6B	–	1.5B	1.5B	1.4B	1.5B	1.5B	1.5B	1.4B	–	1.5B
Medical Products and Therapies	2.1B	1.3B	1.4B	1.3B	1.9B	1.3B	1.3B	1.3B	1.3B	1.2B	1.3B	1.3B	1.3B	1.2B	–	1.2B	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
EMEA	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	738.0M	699.0M	–	779.0M	783.0M	738.0M	–	777.0M	669.0M	688.0M	–	730.0M	744.0M	705.0M	757.0M	707.0M	758.0M	724.0M	–	682.0M
Healthcare Systems and Technologies	801.0M	705.0M	827.0M	773.0M	767.0M	704.0M	784.0M	752.0M	748.0M	667.0M	795.0M	744.0M	743.0M	731.0M	–	735.0M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Asia Pacific	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	647.0M	627.0M	–	720.0M	691.0M	648.0M	–	646.0M	580.0M	549.0M	–	587.0M	576.0M	519.0M	575.0M	557.0M	559.0M	511.0M	–	567.0M
Pharmaceuticals	–	621.0M	668.0M	632.0M	–	581.0M	643.0M	588.0M	602.0M	578.0M	596.0M	580.0M	550.0M	523.0M	–	525.0M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Hillrom	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	715.0M	755.0M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Kidney Care	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1.1B	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Corporate and other	83.0M	90.0M	91.0M	101.0M	98.0M	78.0M	12.0M	17.0M	22.0M	16.0M	18.0M	17.0M	22.0M	30.0M	–	46.0M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Baxter International revenue by business segment, last 4 quarters

Business segment	Q2 FY26	Q1 FY26	Q3 FY25	Q2 FY25	Share
Medical Products and Therapies	$2.1B	$1.3B	$1.3B	$1.9B	72%
Healthcare Systems and Technologies	$801.0M	$705.0M	$773.0M	$767.0M	28%

In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.

Baxter International revenue by product or service, last 4 quarters

Product or service	Q2 FY26	Q1 FY26	Q3 FY25	Q2 FY25	Share
Infusion Therapies and Platforms	$1.7B	–	–	$1.6B	61%
Care and Connectivity Solutions	$502.0M	$435.0M	$473.0M	$474.0M	17%
Advanced Surgery	$331.0M	$304.0M	$306.0M	$296.0M	12%
Front Line Care	$299.0M	$270.0M	$300.0M	$293.0M	10%

In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.

Baxter International revenue by region, last 4 quarters

Region	Q2 FY26	Q1 FY26	Q3 FY25	Q2 FY25	Share
United States	$1.6B	$1.4B	$1.5B	$1.5B	54%
Non-US	$1.4B	$1.3B	–	$1.3B	46%

In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.

Questions and answers

What are Baxter International's business segments?

Medical Products and Therapies and Healthcare Systems and Technologies (as reported for Q2 fiscal 2026).

Which business segment makes the most money for Baxter International?

Medical Products and Therapies: $2.08 billion, or 72% of revenue, in Q2 fiscal 2026.

What are Baxter International's main products and services?

By revenue in Q2 fiscal 2026: Infusion Therapies and Platforms (61%), Care and Connectivity Solutions (17%), Advanced Surgery (12%) and Front Line Care (10%).

Where does Baxter International make its money?

By region in Q2 fiscal 2026: United States (54%) and Non-US (46%).

MoreBaxter International stock overview Baxter International financials Baxter International executive team Baxter International shareholders

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Segments by quarter (USD)

Click a bar to see that period below. Striped bars are calculated fourth quarters; an empty slot means it could not be calculated on the same basis i

AmericasMedical Products and TherapiesEMEAHealthcare Systems and TechnologiesAsia PacificPharmaceuticalsHillromKidney CareOther

Q2 FY26 breakdown

Fiscal quarter ended Jun 30, 2026

Item	Revenue	Share	vs year before
Medical Products and Therapies	USD 2.08B	72.2%	+6.7%
Healthcare Systems and Technologies	USD 801.00M	27.8%	+4.4%
Corporate and otheri	USD 83.00M		-15.3%

Sum of items USD 2.88B; corporate items and eliminations USD 83.00M. Shares are of the items shown. Click an item with › to see its parts.

Also reported by:

All periods

Every item and period in one grid. Purple = calculated; "–" = not available.

Item	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24	Q1 FY24	Q4 FY23	Q3 FY23	Q2 FY23	Q1 FY23	Q4 FY22	Q3 FY22	Q2 FY22	Q1 FY22	Q4 FY21	Q3 FY21	Q2 FY21	Q1 FY21	Q4 FY20	Q3 FY20	Q2 FY20	Q1 FY20	Q4 FY19	Q3 FY19	Q2 FY19	Q1 FY19	Q4 FY18	Q3 FY18	Q2 FY18	Q1 FY18	Q4 FY17	Q3 FY17
Americas	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1.5B	1.6B	–	1.7B	1.6B	1.6B	–	1.5B	1.5B	1.6B	–	1.5B	1.5B	1.4B	1.5B	1.5B	1.5B	1.4B	–	1.5B
Medical Products and Therapies	2.1B	1.3B	1.4B	1.3B	1.9B	1.3B	1.3B	1.3B	1.3B	1.2B	1.3B	1.3B	1.3B	1.2B	–	1.2B	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
EMEA	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	738.0M	699.0M	–	779.0M	783.0M	738.0M	–	777.0M	669.0M	688.0M	–	730.0M	744.0M	705.0M	757.0M	707.0M	758.0M	724.0M	–	682.0M
Healthcare Systems and Technologies	801.0M	705.0M	827.0M	773.0M	767.0M	704.0M	784.0M	752.0M	748.0M	667.0M	795.0M	744.0M	743.0M	731.0M	–	735.0M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Asia Pacific	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	647.0M	627.0M	–	720.0M	691.0M	648.0M	–	646.0M	580.0M	549.0M	–	587.0M	576.0M	519.0M	575.0M	557.0M	559.0M	511.0M	–	567.0M
Pharmaceuticals	–	621.0M	668.0M	632.0M	–	581.0M	643.0M	588.0M	602.0M	578.0M	596.0M	580.0M	550.0M	523.0M	–	525.0M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Hillrom	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	715.0M	755.0M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Kidney Care	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1.1B	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Corporate and other	83.0M	90.0M	91.0M	101.0M	98.0M	78.0M	12.0M	17.0M	22.0M	16.0M	18.0M	17.0M	22.0M	30.0M	–	46.0M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–